Goldman Sachs Group Inc Adverum Biotechnologies, Inc. Transaction History

Goldman Sachs Group Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.75 - $1.26 $2,424 - $4,073	-3,233 Reduced 0.07%	4,552,789 $3.41 Million
Q3 2023 May 14, 2024	BUY	$1.5 - $2.33 $4,849 - $7,532	3,233 Added 0.07%	4,556,022 $6.83 Million
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.33 $7,719 - $11,990	-5,146 Reduced 0.11%	4,556,022 $6.83 Million
Q2 2023 May 14, 2024	BUY	$0.68 - $1.59 $2,386 - $5,579	3,509 Added 0.08%	4,561,168 $7.25 Million
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $2,386 - $5,579	3,509 Added 0.08%	4,561,168 $7.25 Million
Q1 2023 May 14, 2024	BUY	$0.62 - $0.85 $2.75 Million - $3.77 Million	4,433,204 Added 3562.09%	4,557,659 $3.28 Million
Q1 2023 May 11, 2023	BUY	$0.62 - $0.85 $2.83 Million - $3.87 Million	4,557,659 New	4,557,659 $3.28 Million
Q3 2022 May 14, 2024	SELL	$0.96 - $9.68 $86,130 - $868,479	-89,719 Reduced 41.89%	124,455 $118,000
Q3 2022 Nov 10, 2022	SELL	$0.96 - $9.68 $86,130 - $868,479	-89,719 Reduced 41.89%	124,455 $0
Q2 2022 May 14, 2024	SELL	$0.81 - $1.34 $3.51 Million - $5.81 Million	-4,338,615 Reduced 95.3%	214,174 $257,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $40,580 - $67,132	-50,099 Reduced 18.96%	214,174 $257,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $271,351 - $430,191	-220,611 Reduced 45.5%	264,273 $346,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $695,685 - $959,565	-399,819 Reduced 45.19%	484,884 $854,000
Q3 2021 Nov 10, 2021	BUY	$2.08 - $3.6 $1.84 Million - $3.18 Million	884,703 New	884,703 $1.92 Million

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.